Display options
Cite
Schweighofer CD, Wendtner CM. First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther. 2010;3:53-67doi: 10.2147/ott.s3099.
Schweighofer, C. D., & Wendtner, C. M. (2010). First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. OncoTargets and therapy, 353-67. https://doi.org/10.2147/ott.s3099
Schweighofer, Carmen Diana, and Wendtner, Clemens-Martin. "First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab." OncoTargets and therapy vol. 3 (2010): 53-67. doi: https://doi.org/10.2147/ott.s3099
Schweighofer CD, Wendtner CM. First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther. 2010 Jun 24;3:53-67. doi: 10.2147/ott.s3099. PMID: 20616957; PMCID: PMC2895774.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2010 Jun 24;3:53-67. doi: 10.2147/ott.s3099.

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.

OncoTargets and therapy

Carmen Diana Schweighofer, Clemens-Martin Wendtner

Affiliations

  1. Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA;

PMID: 20616957 PMCID: PMC2895774 DOI: 10.2147/ott.s3099

Abstract

The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not set very high. Within clinical trials, the drug demonstrated an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has been correlated with a corresponding survival advantage in patients. However, in the maintenance setting, infectious complications due to severe T cell suppression have been highlighted and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on CLL front-line treatment.

Keywords: CLL; Campath; alemtuzumab; first-line treatment; front-line

References

  1. Leukemia. 2007 May;21(5):956-64 - PubMed
  2. N Engl J Med. 2000 Dec 28;343(26):1910-6 - PubMed
  3. Leuk Lymphoma. 2005 Jan;46(1):87-100 - PubMed
  4. J Clin Oncol. 2005 Oct 1;23(28):7024-31 - PubMed
  5. Leukemia. 2008 Dec;22(12):2257-8 - PubMed
  6. J Clin Oncol. 2003 May 1;21(9):1746-51 - PubMed
  7. Leukemia. 2006 Dec;20(12):2204-7 - PubMed
  8. Blood. 2008 Aug 15;112(4):975-80 - PubMed
  9. Leukemia. 2004 Jun;18(6):1093-101 - PubMed
  10. Hematol J. 2001;2(5):300-6 - PubMed
  11. Leukemia. 2006 Feb;20(2):272-9 - PubMed
  12. Blood. 1983 Oct;62(4):873-82 - PubMed
  13. Blood. 2009 Oct 1;114(14):3052-5 - PubMed
  14. J Biol Chem. 1995 Mar 17;270(11):6088-99 - PubMed
  15. N Engl J Med. 2000 Dec 14;343(24):1750-7 - PubMed
  16. J Clin Oncol. 2005 May 1;23(13):2971-9 - PubMed
  17. J Clin Oncol. 2009 Sep 20;27(27):4578-84 - PubMed
  18. Blood. 2004 Aug 15;104(4):948-55 - PubMed
  19. Blood. 1999 Sep 15;94(6):1840-7 - PubMed
  20. Br J Haematol. 2009 Jan;144(1):95-8 - PubMed
  21. N Engl J Med. 1995 Oct 19;333(16):1052-7 - PubMed
  22. N Engl J Med. 1998 May 21;338(21):1506-14 - PubMed
  23. Leukemia. 2004 Oct;18(10):1637-45 - PubMed
  24. J Clin Oncol. 1997 Apr;15(4):1567-74 - PubMed
  25. Br J Haematol. 1996 Apr;93(1):151-3 - PubMed
  26. Ann Hematol. 2004 Oct;83(10):634-45 - PubMed
  27. J Clin Oncol. 2009 Sep 10;27(26):4378-84 - PubMed
  28. J Clin Oncol. 2006 Oct 1;24(28):4634-41 - PubMed
  29. Br J Clin Pharmacol. 2007 Sep;64(3):278-91 - PubMed
  30. Nature. 1993 Apr 29;362(6423):849-52 - PubMed
  31. Blood. 2002 May 15;99(10):3554-61 - PubMed
  32. Blood. 2011 Aug 25;118(8):2062-8 - PubMed
  33. Leuk Lymphoma. 2009 Oct;50(10):1597-605 - PubMed
  34. Br J Haematol. 1997 Jun;97(3):669-72 - PubMed
  35. Blood. 1995 Mar 15;85(6):1580-9 - PubMed
  36. Blood. 2008 Jun 15;111(12):5446-56 - PubMed
  37. Blood. 1996 Jun 15;87(12):4990-7 - PubMed
  38. Blood. 2006 Feb 1;107(3):885-91 - PubMed
  39. Leuk Lymphoma. 2002 Sep;43(9):1755-62 - PubMed
  40. J Clin Oncol. 2006 Jan 20;24(3):437-43 - PubMed
  41. Blood. 2006 Jun 1;107(11):4563-9 - PubMed
  42. Med Sci Monit. 2005 Oct;11(10):PI71-9 - PubMed
  43. Haematologica. 2002 Jul;87(7):695-700; discussion 700 - PubMed
  44. Cancer. 2009 Jan 15;115(2):373-80 - PubMed
  45. N Engl J Med. 2000 Dec 14;343(24):1799-801 - PubMed
  46. Blood. 1993 Aug 1;82(3):807-12 - PubMed
  47. Cancer. 2003 Dec 15;98(12):2657-63 - PubMed
  48. J Clin Oncol. 2009 Aug 20;27(24):3994-4001 - PubMed
  49. Leukemia. 2009 Nov;23(11):1980-8 - PubMed
  50. Leuk Lymphoma. 2007 Dec;48(12):2424-36 - PubMed
  51. J Clin Oncol. 2007 Mar 1;25(7):793-8 - PubMed
  52. N Engl J Med. 2003 May 1;348(18):1764-75 - PubMed
  53. Leuk Res. 2010 Mar;34(3):284-8 - PubMed
  54. J Clin Oncol. 2005 Jun 20;23(18):4079-88 - PubMed
  55. Cancer. 2008 Mar 15;112(6):1288-95 - PubMed
  56. Cancer Invest. 2005;23(6):488-96 - PubMed
  57. J Clin Oncol. 2009 Feb 1;27(4):498-503 - PubMed
  58. J Clin Oncol. 1998 Oct;16(10):3257-63 - PubMed
  59. Lancet. 2007 Jul 21;370(9583):230-239 - PubMed
  60. J Clin Oncol. 2007 Dec 1;25(34):5448-57 - PubMed
  61. Br J Haematol. 2009 Jan;144(1):78-85 - PubMed
  62. J Clin Oncol. 2006 May 20;24(15):2337-42 - PubMed
  63. Blood. 2009 Oct 15;114(16):3382-91 - PubMed
  64. Tissue Antigens. 1990 Mar;35(3):118-27 - PubMed
  65. Blood. 2006 Jul 15;108(2):473-9 - PubMed
  66. Cancer Genet Cytogenet. 1986 Dec;23(4):321-8 - PubMed
  67. Haematologica. 2005 Oct;90(10):1435-6 - PubMed
  68. Blood. 1998 Jun 1;91(11):4342-9 - PubMed
  69. J Clin Oncol. 2007 Dec 10;25(35):5616-23 - PubMed
  70. Cancer. 2008 Oct 15;113(8):2110-8 - PubMed
  71. Blood. 2002 Aug 1;100(3):768-73 - PubMed
  72. J Mol Med (Berl). 1999 Feb;77(2):266-81 - PubMed
  73. Haematologica. 2007 Sep;92(9):1242-5 - PubMed
  74. Blood. 2008 Oct 15;112(8):3322-9 - PubMed
  75. Blood. 1999 Sep 15;94(6):1848-54 - PubMed
  76. Blood. 2004 May 1;103(9):3278-81 - PubMed

Publication Types